Stocklore

Vertex Pharmaceuticals Inc (VRTX)

Biotech & Health · US stock

Company overview

Vertex Pharmaceuticals. A biotech that monopolizes the market with the cystic-fibrosis (CF) drug Trikafta.

What is the Biotech & Health sector?

Pharma, biotech, and medical devices. Driven by trial-result events.

Vertex Pharmaceuticals Inc is classified under the Biotech & Health sector. See peers below.

ETFs holding Vertex Pharmaceuticals Inc

Per SEC N-PORT · 2026-03-31 · by weight · factual

XLVState Street(R) Health Care Select Sector SPDR(R) ETF
2.14%
JEPIJPMorgan Equity Premium Income ETF
1.24%
QQQMInvesco NASDAQ 100 ETF
0.68%
QQQInvesco QQQ Trust, Series 1
0.64%
RSPInvesco S&P 500 Equal Weight ETF
0.21%
SPY
0.20%
VOOVANGUARD 500 INDEX FUND
0.20%
IVViShares Core S&P 500 ETF
0.20%
VTIVANGUARD TOTAL STOCK MARKET INDEX FUND
0.18%
ITOTiShares Core S&P Total U.S. Stock Market ETF
0.18%

VRTX on Stocklore

  • Revenue by segment — segment weights verified from SEC filings, YoY changes, growth drivers and concentration
  • Financials & earnings quality — 6 metrics (FCF conversion, ROIC, net debt, etc.) to gauge profit quality
  • 13F institutional holdings — holdings and weight changes of major institutions (45-day delay)
  • Sector-relative metrics — valuation and growth vs the Biotech & Health average
See full VRTX analysis →

Peers · Biotech & Health

VRTX FAQ

What is Vertex Pharmaceuticals Inc (VRTX)?

Vertex Pharmaceuticals. A biotech that monopolizes the market with the cystic-fibrosis (CF) drug Trikafta.

What sector is Vertex Pharmaceuticals Inc in?

Vertex Pharmaceuticals Inc is classified under Biotech & Health. Pharma, biotech, and medical devices. Driven by trial-result events.

Where can I analyze Vertex Pharmaceuticals Inc (VRTX) stock?

On Stocklore you can see VRTX's financials & earnings quality, 13F institutional holdings, and sector-relative metrics in one place. This page is for information and tools — not a buy/sell recommendation.

Data sources: SEC EDGAR (financials & filings), 13F (institutional holdings, 45-day delay), market data. This page is for information and analysis tools — it does not recommend buying or selling any security. Investment decisions and responsibility are your own.

Not an investment adviser and not personalized investment advice; not a discretionary management service. No trade recommendations, no target prices, no execution or brokerage. We do not recommend or guarantee any purchase, sale, or returns. Investment decisions and their outcomes are your own.

Stocklore · CEO Lee Seung-jae · Business reg. no. 764-36-01607 · E-commerce permit 2026-Jeonju Wansan-0476 · Tel +82-70-7954-4939 · S120, Rm 302, 3F, 21 Jungsanjungang-ro, Wansan-gu, Jeonju, Jeonbuk, Korea